Bristol-Myers Squibb: A Dividend Gem With Hidden Upside In 2026

Bristol-Myers Squibb is upgraded to Buy as its growth portfolio now offsets legacy declines, validating a bullish contrarian thesis. BMY's 2026 guidance and Q4 2025 results exceeded consensus, with management consistently under-promising and over-delivering, setting up strong risk/reward. Patent cliffs for Eliquis and Opdivo loom in 2028, but a robust pipeline—seven registrational readouts in 2026—offers multiple upside catalysts.

Seeking Alpha • Feb 6, 2026

Bristol Myers Squibb CEO: Richest product pipeline we've had in the last decade

Chris Boerner, Bristol Myers Squibb CEO, joins CNBC's "Power Lunch" to discuss the company's quarterly earnings results, the drug pipeline and much more.

CNBC Television • Feb 6, 2026

Bristol Myers Just Crushed Earnings, and the Real Catalyst Hasn't Even Hit Yet

Bristol Myers Squibb (NYSE:BMY) reported Q4 2025 revenue of $12.5 billion, essentially flat year-over-year, with full-year 2025 revenue reaching $48.2 billion.

24/7 Wall Street • Feb 5, 2026

Bristol Myers Flags Data-Rich 2026 After Solid Quarter

Bristol Myers Squibb & Co. (NYSE: BMY) reported fourth-quarter 2025 revenues of $12.50 billion on Thursday, beating the consensus of $12.281 billion, a 1% increase year over year.

Benzinga • Feb 5, 2026

Dow Tumbles Over 400 Points; Bristol Myers Reports Strong Q4 Results

Bristol Myers Squibb & Co. (NYSE:BMY) reported better-than-expected results for the fourth quarter.

Benzinga • Feb 5, 2026

Why Bristol Myers Squibb Stock Topped the Market Today

Investors were impressed by the company's performance in the final quarter of 2025. It beat analyst expectations on both the top and bottom lines.

The Motley Fool • Feb 5, 2026

Bristol Myers forecasts upbeat 2026, expecting Eliquis price cut to pay off

Bristol Myers Squibb on Thursday forecast 2026 results above Wall Street estimates, saying that price cuts to its blood thinner Eliquis will help drive up revenue.

Reuters • Feb 5, 2026

Bristol Myers Rises Inside A Buy Zone On Street-Beating 2026 Outlook

Bristol Myers Squibb stock rose moderately Thursday on better-than-expected fourth-quarter metrics and a strong 2026 outlook.

Investors Business Daily • Feb 5, 2026

Bristol Myers Stock Rises. Why Fourth-Quarter Earnings Are Exciting Investors.

Bristol Myers Squibb issues an especially upbeat outlook for 2026.

Barrons • Feb 5, 2026

Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2025

PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2025.

Business Wire • Feb 5, 2026